The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCaspian Sunrise Regulatory News (CASP)

Share Price Information for Caspian Sunrise (CASP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.40
Bid: 3.30
Ask: 3.50
Change: 0.05 (1.49%)
Spread: 0.20 (6.061%)
Open: 3.35
High: 3.40
Low: 3.35
Prev. Close: 3.35
CASP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

29 Jan 2021 10:15

RNS Number : 3653N
Caspian Sunrise plc
29 January 2021
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

CASPIAN SUNRISE PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Daehan New Pharm Co. Ltd.

City and country of registered office (if applicable)

Seoul, South Korea

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

22 December 2020

6. Date on which issuer notified (DD/MM/YYYY):

26 January 2021

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuervii

Resulting situation on the date on which threshold was crossed or reached

10.77%

Zero

10.77%

224,830,964

Position of previous notification (if

applicable)

Zero

Zero

Zero

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(DTR5.1)

Indirect

 (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

224,830,964

Zero

10.77%

zero

SUBTOTAL 8. A

Zero

Zero

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Daehan New Pharm Co. Ltd.

10.77%

Zero

10.77%

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

Seoul, South Korea

Date of completion

28 January 2021

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLBLMMTMTMTBAB
Date   Source Headline
24th May 20197:52 amRNSBNG operational update
24th May 20197:00 amRNSAnnual Report and Financial Statements
9th May 20197:05 amRNSOperational Update
15th Apr 20197:00 amRNSBNG operational update
13th Mar 20199:30 amRNSBNG operational update
25th Jan 20197:00 amRNSNon-Executive Director Appointment
22nd Jan 20197:00 amRNSOperational, 3A Best and Shareholding Update
17th Jan 20197:00 amRNSBNG operational update
17th Dec 201811:42 amRNSExercise of Options
13th Dec 20182:23 pmRNSDirector/PDMR Shareholding
28th Nov 201811:05 amRNSBNG Operational Update
13th Nov 20187:00 amRNS3A Best acquisition update
5th Nov 20187:00 amRNSBNG Operational Update
28th Sep 20187:00 amRNSInterim Results for the period ended 30 June 2018
1st Aug 20187:00 amRNSBNG Deep Well Operational Update
19th Jun 20183:58 pmRNSResult of AGM
29th May 20187:00 amRNSOperational Update & 3A Best Acquisition Update
14th May 20187:00 amRNSFinal Results
9th May 20187:00 amRNSOperational Update
19th Mar 201811:00 amRNSPrice Monitoring Extension
19th Mar 20187:00 amRNSOperational Update
12th Feb 20187:00 amRNSBNG Operational Update
1st Feb 20189:34 amRNSUpdated Corporate Presentation
31st Jan 20187:00 amRNSOperational & Corporate Update
23rd Jan 201812:03 pmRNSPDMR Notification
4th Jan 20187:00 amRNSOperational Update
14th Dec 20177:00 amRNSBNG Operational Update
27th Nov 20178:48 amRNSShareholding Update
27th Nov 20177:00 amRNSBNG Operational Update
21st Nov 20171:01 pmRNSUpdated Corporate Presentation
20th Nov 20177:00 amRNSBNG Operational Update
10th Nov 201711:31 amRNSCorrection: Shareholding Update
10th Nov 20177:00 amRNSShareholding Update
8th Nov 20177:00 amRNSInvestor Evening
27th Oct 20177:00 amRNSBNG Contract Area Early Licence Renewal
23rd Oct 20177:00 amRNSBNG Operational Update
2nd Oct 20177:00 amRNSOperational Update
20th Sep 20177:00 amRNSInterim Results
30th Aug 201711:32 amRNSShareholding Update
8th Aug 20177:00 amRNSBNG Operational Update
4th Aug 20174:12 pmRNSShareholding Update
3rd Jul 20177:00 amRNSOperational Update
13th Jun 20172:15 pmRNSResult of AGM
1st Jun 20179:27 amRNSNotification of Major Interest in Shares
1st Jun 20177:00 amRNSCompletion of the Baverstock Merger
26th May 20177:00 amRNSBaverstock Merger Completion
15th May 20177:00 amRNSFinal Results
12th May 20171:13 pmRNSFinal Approval Received for Baverstock Merger
10th May 201710:27 amRNSOperational Update - Spudding of Well 144
8th May 20177:00 amRNSBNG Operational Merger / Baverstock Merger Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.